IMR Press / EJGO / Volume 39 / Issue 1 / DOI: 10.12892/ejgo3601.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Pilot study of megestrol acetate and hydralazine in gynecologic adenocarcinomas
Show Less
1 Cancer Treatment Centers of America, Division of Gynecologic Oncology, Newnan, GA, USA
Eur. J. Gynaecol. Oncol. 2018, 39(1), 41–43;
Published: 10 February 2018

Background: DNA promoter methylation serves as an alternative to gene mutation in silencing genes. The progesterone receptor, a target for cancer therapy, has been shown to be silenced in this manner. The object of the study was to determine if patients taking hydralazine as a global demethylating agent would have tumor stabilization or response from using sequential megestrol acetate and secondarily whether the tumor would show changes consistent with the demethylation. Materials and Methods: Heavily pretreated women with gynecologic adenocarcinomas were enrolled on an institutional review approved study. Results: Five patients were enrolled on this initial study. Three patients continued therapy beyond the first four week cycle. These patients had progression free intervals of six, seven, and nine months, respectively. All of the evaluable patients had negative staining for progesterone receptor prior to study. All three patients who finished at least one cycle of therapy had repeat biopsies that demonstrated their tumors stained positively for progesterone receptor. Conclusions: In this pilot study, three patients had progression free intervals of ≥ six months and their tumors which previously stained negatively for progesterone receptor stained positively for progesterone receptor after treatment with hydralazine.
Back to top